SAN FRANCISCO, March 29, 2017 /PRNewswire/ -- Spiral Therapeutics, Inc. today announced the signature of an option agreementwith Bionure Farma, S.L. for the worldwide exclusive rights to Bionure's lead candidate, BN201 and to BN119 in the field of otolaryngology for aggregate payments of up to US$4.86 million plus sales-based royalties.
"We are very pleased to acquire the opportunity to develop BN201 and BN119 for inner ear disorders and build on Bionure's excellent pre-clinical work around its candidates," said Hugo Peris, founder and CEO of Spiral Therapeutics. "This agreement will accelerate Spiral's vision to become a leading player in the fast-growing inner ear space."
"Spiral has rapidly built strong expertise in the otology field since its foundation last year," said Albert Zamora, CEO of Bionure. "We are pleased to partner with Spiral in progressing our drugs in this important therapeutic area with many unmet medical needs."
About BN201 and BN119
Bionure's compounds BN201 and BN119 are two SGK agonists with remyelinating and neuroprotective activity. Bionure has developed BN201 for the treatment of rare ophthalmic indications associated with multiple sclerosis and expects to receive Clinical Trial Authorization for BN201 in the UK in Q2 2017. BN201 and BN119 could be useful in preventing and treating debilitating inner ear disorders, like sensorineural hearing loss.
Bionure is a late-preclinical drug development company based in Barcelona, Spain focused on developing first-in-class SGK agonists for the treatment of rare ophthalmic diseases. Bionure's lead candidate BN201 is a small molecule, new chemical entity that promotes neuroprotection and remyelination. Bionure plans to start clinical trials in 2017. www.bionure.com
About Spiral Therapeutics
Spiral Therapeutics is a late stage preclinical company focused on the development of first-in-class products targeting inner ear disorders. Spiral's lead candidate LPT99 for prevention of hearing loss is expected to reach clinical stage in 2018. Spiral is headquartered in San Francisco, CA and has an R&D office in Barcelona, Spain. www.spiraltx.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spiral-therapeutics-acquires-an-exclusive-option-to-develop-two-neuroprotective-agents-for-the-treatment-of-inner-ear-disorders-300430547.html
SOURCE Spiral Therapeutics, Inc.
Subscribe to our Free Newsletters!
Erythropoietin is a hormone secreted by kidneys in response to low oxygen levels in tissues ...
Local anesthesia is a type of anesthesia generally used to block pain sensation only in a specific ...
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...View All